AZN Stock Recent News

CAMBRIDGE, United Kingdom , March 17, 2025 /PRNewswire/ -- IgniteData has announced a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) and Cambridge University Hospitals NHS Foundation Trust (CUH) to launch its Archer tool for clinical data integration in an ongoing Phase 3 study sponsored by AstraZeneca. This collaboration marks a significant milestone in IgniteData's aim of transforming clinical trials through automation and digital innovation.

The deal includes the Belgian biotech's vivo cell-therapy platform, which modifies immune cells within the patient's body, potentially increasing access to treatment and reducing costs.

AstraZeneca PLC (LSE:AZN) has agreed to pay up to $1 billion to buy EsoBiotec, a Belgian company that has made clinical breakthroughs in cell therapy, where immune cells are engineered directly within the patient's body. The FTSE 100 giant will pay $425 million when the deal closes, which is expected before June, plus up to a further $575 million based on development and regulatory milestones.

Drugmaker AstraZeneca on Monday said it will buy biotechnology firm Esobiotec for upto $1 billion.

Acquisition includes EsoBiotec's world-leading in vivo delivery platform with potential to transform cell therapy Acquisition includes EsoBiotec's world-leading in vivo delivery platform with potential to transform cell therapy

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Erin Andrews have teamed up as part of a national public health campaign to educate and empower people to Get Body Checked Against Cancer. Erin is a passionate entrepreneur, national sports broadcaster, podcast host, hockey fan and wife — and cancer survivor. The Get Body Checked Against Cancer campaign encourages people to take control of their health by talking with their doctors about their cancer risk factors and whether cancer screenings a.

This biopharmaceutical stock is nearing a buy point of a cup-with-handle base. The post AstraZeneca Stock Nears Buy Point After Long Run In Declining Market appeared first on Investor's Business Daily.

UBS has reaffirmed its 'buy' rating on AstraZeneca PLC (LSE:AZN) with a 12-month price target of 14,200p, with the bank is optimistic about the potential of its blood pressure drug, baxdrostat. The Anglo-Swedish drugs giant is developing baxdrostat as part of a new class of treatments called aldosterone synthase inhibitors (ASIs).

AstraZeneca PLC has edged closer to its aim of generating $80 billion in revenue come 2030 on positive results from a trial of Imfinzi, according to analysts. Shore Capital doubled down on a ‘buy' rating following Friday's update that a combination of the drug and chemotherapy yielded promising results.

A new treatment combining AstraZeneca PLC's (LSE:AZN) drug Imfinzi with chemotherapy has shown promising results for people with early-stage stomach and oesophageal cancer, making it less likely that their cancer will return after surgery. The MATTERHORN trial, a large international study, tested whether adding Imfinzi to standard chemotherapy before and after surgery could improve patient outcomes.